Radioimmunotherapy can cure AIDS
-------------------------------------------------- ------------------------------
Author: Source: China Public Technology Net Posted by: Liu Bin Category: News Scan Date: 2009-02-26 Today View / Total View: 55/55

Albert耶什American University. Albert Einstein College of Medicine scientists will be carrying antibodies to radioactive carriers have selectively destroyed by micro-organisms and HIV infected cells. This Radioimmunotherapy (RIT) is expected to be able to treat infectious diseases, including AIDS and the virus-induced cancer. This is the Institute of nuclear medicine and microbiology and immunology associate professor特琳娜Illueca. Test黛德watts in a AAAS symposium on the above-mentioned viewpoints.

   

Currently only used for the treatment of cancer of the RIT are only made use of an antibody against an antigen that the human body characteristics. Put radioactive material with a special antibody binding, radiation will be aimed at the expression of the corresponding antigen cells, which would reduce the harm to other organizations. This specific treatment methods are the existing level of radiation therapy could not be done.

   

RIT was first developed for cancer treatment, the current in the treatment of immune cells originate from non-Hodgkin's lymphoma received a great success. W黛德test in recent years and Professor of Microbiology and Immunology阿托罗study.卡萨德沃together to improve the technology it used to treat fungal, bacterial and viral infections caused by.

   

Viruses and cancer cells because of the significant differences between the radioimmunotherapy for HIV face a serious challenge. Viruses are small protein DNA or RNA wrapped with tiny biological. Easy, not easy to be destroyed and recovery capability makes it very easy for it out of the radiation, but it also has the ability to quickly resume the injury. Are more complex, HIV can escape the immune cells so that they fall far short of antibodies.

   

"Our approach is not to target the virus itself, but rather stay lymphocyte virus." Rugova said黛德test. "Fortunately lymphocytes belong to the body of the radiation-sensitive cells."

   

Researchers designed this RIT is glycoprotein 41 (gp41) antibody and radioisotope Bismuth -213 with a special composition of ligand molecules. Select gp41 antibody because of its combination with the gp41 antigen in HIV infected cells have the exact expression of surface energy. In addition, with the HIV glycoprotein different from the other, gp41 antigen does not normally enter into the bloodstream, so that the radioactive tag will not lose the target antibody. Bismuth -213 choice because it has several characteristics, including the half-life of 46 minutes. Such a short half-life to facilitate the treatment of the operation, but also easy to play a role in radioactive antibody. Bismuth -213 in 4 hours and will be gone.

   

Researchers have proven that this treatment can effectively clear the laboratory and two different mouse model of HIV were HIV-infected human cells. At present, the Group being the therapy efficacy and safety of sub-clinical trials for HIV patients in Phase Ⅰ Clinical Trial preparation to do.

   

RIT was also the treatment of HIV infection caused by the potential of cancer, such as cervical cancer (some with the human papilloma infection) and liver cancer (with the hepatitis B virus infection). These cancers account for almost a quarter of all cancers. "A lot of virus-related cancer will continue to express viral antigens." Rugova said黛德test. "As in other parts of the body will not have these antigens, so the treatment of virus-related cancer RIT are very good targeted for patients with low toxicity."
 
 
Author:
Source: China Public Technology Net
Posted by: Liu Bin